A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)

Daniel R. Greenwald, Hailun Li, Selina M. Luger, Ronald S. Go, David King, Taral Patel, Randy D. Gascoyne, Jill Kolesar, Brad S. Kahl, Sandra Horning

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

Original languageEnglish
Article number46
JournalJournal of Hematology and Oncology
Volume6
Issue number1
DOIs
StatePublished - 2013

Keywords

  • Diffuse large B cell lymphoma
  • MAP kinase signaling
  • NHL
  • Sorafenib

Fingerprint

Dive into the research topics of 'A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)'. Together they form a unique fingerprint.

Cite this